Business Context and Reporting Period
Company: Rockwell Medical, Inc. (RMTI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2026
Event: Results of the 2026 Annual Meeting of Stockholders held on June 12, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Four proposals were submitted to stockholders. The voting outcomes were as follows:
- Proposal One (Election of Directors):
- Joseph Dawson: 9,812,114 For; 869,022 Against; 330,731 Abstain. Result: Approved.
- Joan Lau, Ph.D.: 9,890,379 For; 729,615 Against; 391,873 Abstain. Result: Approved.
- Proposal Two (Advisory Executive Compensation): 8,232,918 For; 2,682,354 Against; 96,595 Abstain. Result: Approved.
- Proposal Three (Ratification of Auditor): Ratification of EisnerAmper LLP. 22,996,530 For; 698,744 Against; 118,432 Abstain. Result: Approved.
- Proposal Four (Reverse Stock Split): Amendment to Certificate of Incorporation to effect a reverse stock split. 16,993,038 For; 6,597,036 Against; 223,632 Abstain. Result: Approved.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on operations, or new risk factors beyond the approval of the reverse stock split, which may impact share price and liquidity.
Investor Verification Checklist
- Verify the specific ratio of the approved reverse stock split (Proposal Four) in subsequent filings or press releases.
- Confirm the effective date of the reverse stock split and its impact on the number of shares outstanding.
- Review the terms of the new three-year term for the elected Class II directors (expiring 2029).
- Monitor the company's compliance with Nasdaq Capital Market listing standards following the stock split.